Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Science will present at the Wedbush 2014 Life Sciences Management Access Conference at 10:20 a.m. EDT on Tuesday, August 12, 2014, in New York City. Mr. Pernock and Mr. Weaver will discuss the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Help employers find you! Check out all the jobs and post your resume.
